Key facts
- Notable investors include Company K Partners, KD Investments (private placement), Korean Investment Partners, Quad Asset Management, Young Investment Group Industry.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for AGATHONBIO
- ·The full record, as it builds
Funding rounds
No funding rounds for AGATHONBIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AGATHONBIO
Operator of a biotechnology company intended to support new drug development, synthetic development, and production of pharmaceutical raw materials. The company offers GMP-certified facilities, advanced automation systems, and a strong patent portfolio, enabling pharmaceutical companies, research institutions, and biotech firms to efficiently produce high-quality raw materials and advance drug research and development.
- Sector
- Healthcare
- HQ
- Hwaseong, South Korea
- Founded
- 2019
- Employees
- 28
- Website
- agathonbio.com/
- Ownership
- Privately Held (backing)
AGATHONBIO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AGATHONBIO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AGATHONBIO in its N-PORT filings yet. We sweep new filings monthly.